Public Employees Retirement System of Ohio Has $9.17 Million Position in Jazz Pharmaceuticals PLC $JAZZ

Public Employees Retirement System of Ohio boosted its holdings in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 19.0% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 48,490 shares of the specialty pharmaceutical company’s stock after acquiring an additional 7,744 shares during the quarter. Public Employees Retirement System of Ohio’s holdings in Jazz Pharmaceuticals were worth $9,167,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in JAZZ. Capital World Investors increased its stake in shares of Jazz Pharmaceuticals by 4.4% during the 4th quarter. Capital World Investors now owns 2,666,602 shares of the specialty pharmaceutical company’s stock worth $453,322,000 after purchasing an additional 111,735 shares during the last quarter. Ameriprise Financial Inc. lifted its stake in shares of Jazz Pharmaceuticals by 11.4% in the 2nd quarter. Ameriprise Financial Inc. now owns 1,867,399 shares of the specialty pharmaceutical company’s stock valued at $198,159,000 after purchasing an additional 191,637 shares during the last quarter. Franklin Resources Inc. boosted its holdings in Jazz Pharmaceuticals by 164.0% in the fourth quarter. Franklin Resources Inc. now owns 1,818,911 shares of the specialty pharmaceutical company’s stock worth $309,215,000 after purchasing an additional 1,129,995 shares in the last quarter. Bank of New York Mellon Corp increased its position in Jazz Pharmaceuticals by 44.5% during the first quarter. Bank of New York Mellon Corp now owns 1,679,371 shares of the specialty pharmaceutical company’s stock worth $317,485,000 after buying an additional 517,514 shares during the last quarter. Finally, Fuller & Thaler Asset Management Inc. lifted its position in shares of Jazz Pharmaceuticals by 3.1% in the fourth quarter. Fuller & Thaler Asset Management Inc. now owns 1,677,132 shares of the specialty pharmaceutical company’s stock worth $285,113,000 after buying an additional 50,996 shares during the last quarter. 89.14% of the stock is owned by institutional investors.

Insider Buying and Selling

In other news, Director Rick E. Winningham sold 2,741 shares of the firm’s stock in a transaction on Friday, May 22nd. The shares were sold at an average price of $241.57, for a total value of $662,143.37. Following the sale, the director owned 9,567 shares in the company, valued at approximately $2,311,100.19. This trade represents a 22.27% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Heather Ann Mcsharry sold 2,000 shares of the business’s stock in a transaction on Friday, May 22nd. The stock was sold at an average price of $241.00, for a total transaction of $482,000.00. Following the transaction, the director directly owned 18,449 shares in the company, valued at $4,446,209. This trade represents a 9.78% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 13,098 shares of company stock valued at $3,131,906 in the last ninety days. Company insiders own 4.10% of the company’s stock.

Jazz Pharmaceuticals Price Performance

NASDAQ JAZZ opened at $255.43 on Tuesday. The stock has a 50-day simple moving average of $237.89 and a 200 day simple moving average of $204.06. Jazz Pharmaceuticals PLC has a twelve month low of $105.00 and a twelve month high of $257.00. The stock has a market capitalization of $16.05 billion, a PE ratio of -12,765.12, a P/E/G ratio of 0.22 and a beta of 0.32. The company has a debt-to-equity ratio of 0.95, a quick ratio of 1.85 and a current ratio of 2.04.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its earnings results on Tuesday, March 31st. The specialty pharmaceutical company reported $6.34 earnings per share (EPS) for the quarter. The firm had revenue of $1.07 billion for the quarter. Jazz Pharmaceuticals had a return on equity of 14.56% and a net margin of 0.66%. Research analysts anticipate that Jazz Pharmaceuticals PLC will post 21.9 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on JAZZ. Weiss Ratings raised Jazz Pharmaceuticals from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday, June 29th. TD Cowen increased their price target on Jazz Pharmaceuticals from $220.00 to $275.00 and gave the company a “buy” rating in a report on Wednesday, May 6th. Raymond James Financial reiterated an “outperform” rating and set a $239.00 price target on shares of Jazz Pharmaceuticals in a report on Wednesday, May 6th. Robert W. Baird set a $252.00 price objective on shares of Jazz Pharmaceuticals in a research note on Wednesday, May 6th. Finally, Wells Fargo & Company upped their price objective on shares of Jazz Pharmaceuticals from $265.00 to $285.00 and gave the stock an “overweight” rating in a report on Tuesday, July 14th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, Jazz Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $259.06.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.